uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance
Univ Antwerp, Dept Med Microbiol, Vaccine & Infect Dis Inst, B-2020 Antwerp, Belgium..
Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands..
AstraZeneca, Infect Global Med Dev, Macclesfield, Cheshire, England..
GlaxoSmithKline, Infect Dis Therapy Area Unit, London, England..
Show others and affiliations
2016 (English)In: Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, E-ISSN 1460-2091, Vol. 71, no 2, 290-295 p.Article, review/survey (Refereed) PublishedText
Abstract [en]

Antibiotic resistance (ABR) is a global public health threat. Despite the emergence of highly resistant organisms and the huge medical need for new drugs, the development of antibacterials has slowed to an unacceptable level worldwide. Numerous government and non-government agencies have called for public-private partnerships and innovative funding mechanisms to address this problem. To respond to this public health crisis, the Innovative Medicines Initiative Joint Undertaking programme has invested more than a,not sign660 million, with a goal of matched contributions from the European Commission and the European Federation of Pharmaceutical Industries and Associations, in the development of new antibacterial strategies. The New Drugs for Bad Bugs (ND4BB) programme, an Innovative Medicines Initiative, has the ultimate goal to boost the fight against ABR at every level from basic science and drug discovery, through clinical development to new business models and responsible use of antibiotics. Seven projects have been launched within the ND4BB programme to achieve this goal. Four of them will include clinical trials of new anti-infective compounds, as well as epidemiological studies on an unprecedented scale, which will increase our knowledge of ABR and specific pathogens, and improve the designs of the clinical trials with new investigational drugs. The need for rapid concerted action has driven the funding of seven topics, each of which should add significantly to progress in the fight against ABR. ND4BB unites expertise and provides a platform where the commitment and resources required by all parties are streamlined into a joint public-private partnership initiative of unprecedented scale.

Place, publisher, year, edition, pages
2016. Vol. 71, no 2, 290-295 p.
National Category
Infectious Medicine Pharmaceutical Sciences
URN: urn:nbn:se:uu:diva-299009DOI: 10.1093/jac/dkv339ISI: 000372427600003PubMedID: 26568581OAI: oai:DiVA.org:uu-299009DiVA: diva2:948741
Available from: 2016-07-13 Created: 2016-07-13 Last updated: 2016-07-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Karlén, Anders
By organisation
Organic Pharmaceutical Chemistry
In the same journal
Journal of Antimicrobial Chemotherapy
Infectious MedicinePharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 72 hits
ReferencesLink to record
Permanent link

Direct link